Chronic Pain Indications Will Be Harder To Come By, FDA Says
A general chronic pain indication may elude Eli Lilly's Cymbalta near the finish line because FDA has changed its thinking about the evidence needed to support the claim
A general chronic pain indication may elude Eli Lilly's Cymbalta near the finish line because FDA has changed its thinking about the evidence needed to support the claim